The Children's Place, Inc. has 4 buy ratings, 4 holds and 0 sells even after the stock tumbled -5.83% from its high of $125.3 to a $2.06 billion market value through last close. Teachers Advisors LLC now owns 123,810 shares of the company's stock worth $5,922,000 after buying an additional 15,904 shares during the period. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company's stock.
Other institutional investors have also added to or reduced their stakes in the company. Sanford C. Bernstein began coverage on Ionis Pharmaceuticals in a research note on Thursday, July 27th. Utah Retirement Systems now owns 22,000 shares of the company's stock worth $884,000 after buying an additional 100 shares in the last quarter.
Total shares held by institutions as of the most recent company filings are 120,559,675 with a reported 8,126,303 bought and 2,738,219 sold. TheStreet upgraded Ionis Pharmaceuticals from a "d+" rating to a "c-" rating in a research note on Wednesday, July 5th. Wellington Management Group LLP now owns 9,360,553 shares of the company's stock valued at $376,295,000 after buying an additional 3,364,621 shares in the last quarter. Finally, Opus Point Partners Management LLC increased its position in shares of Ionis Pharmaceuticals by 1.5% in the fourth quarter. World Asset Management Inc now owns 5,427 shares of the company's stock valued at $218,000 after buying an additional 1,163 shares in the last quarter. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Teachers Advisors LLC increased its position in shares of Ionis Pharmaceuticals by 14.7% in the fourth quarter. Finally, Jane Street Group LLC boosted its position in Ionis Pharmaceuticals by 3.9% in the first quarter.
Zacks Investment Research downgraded shares of Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals (IONS) traded down 0.58% during trading on Thursday, hitting $48.03. Hanseatic Management Services Inc. acquired a new stake in shares of Ionis Pharmaceuticals during the first quarter valued at approximately $138,000. The company's shares opened today at $48.26. Vanguard Group Inc. now owns 9,437,796 shares of the company's stock valued at $379,399,000 after buying an additional 384,830 shares in the last quarter. On average, equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post $0.05 EPS for the current year. Insiders have sold 54,379 shares of company stock worth $2,946,052 in the last quarter. The stock's 50 day moving average price is $53.06 and its 200-day moving average price is $46.75. During the last 52 weeks, the (NASDAQ:IONS) price has been as high as $60.01 and as low as $24.58. Currently, Ionis Pharmaceuticals Inc has an average volume of 1.41M. More interesting news about Ionis Pharmaceuticals Inc (NASDAQ:IONS) were released by: Prnewswire.com and their article: "Ionis Earns $10 Million Milestone Payment from Biogen for Advancing a New ..." published on July 17, 2017 as well as Prnewswire.com's news article titled: "Ionis Pharmaceuticals to Hold Second Quarter 2017 Financial Results Webcast" with publication date: July 25, 2017.
The drug discovery and development company posted revenue of $104.2 million in the period, beating Street forecasts. The business's revenue was up 170.7% on a year-over-year basis.
They expect $-0.06 EPS, up 683.33% or $0.41 from last year's $-0.47 per share. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of USA and worldwide copyright legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/08/09/ionis-pharmaceuticals-inc-nasdaqions-price-target-raised-to-50-00-at-stifel-nicolaus.html. The shares were sold at an average price of $59.29, for a total value of $592,900.00. The stock, as of recent close, has shown weekly downbeat performance of -5.16% which was maintained at -6.19% in 1-month period, and is up 1% in this year. Institutional investors own 88.77% of the company's stock. Following the transaction, the chairman now owns 53,014 shares of the company's stock, valued at approximately $2,780,584.30. The disclosure for this purchase can be found here. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Company's divisions include Ionis Core and Akcea Therapeutics.